Since Prurisol is effective in some patients where Otezla is not, I think Celgene would be a perfect partner. With the addition of P, Celgene will dominate the oral non-biologics market and no need to worry about competing. They have the experience in running Phase 3 trials, plus a strong marketing and sales team. They should give Leo a call. Oh wait, they did that before.

"I will add that it is ironic that you mentioned Celgene, as they have recently contacted us, but only requesting information that is publicly available."

http://seekingalpha.com/article/1273221-an-in...ceutix-ceo